

Serge Korjian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11857219/publications.pdf>

Version: 2024-02-01

49
papers

2,444
citations

471509

17
h-index

223800

46
g-index

49
all docs

49
docs citations

49
times ranked

4092
citing authors

#	ARTICLE	IF	CITATIONS
1	Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design. <i>Clinical Cardiology</i> , 2022, , .	1.8	3
2	Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity. <i>Journal of the American Heart Association</i> , 2022, 11, e024754.	3.7	13
3	Digital technologies and the democratization of clinical research: Social media, wearables, and artificial intelligence. <i>Contemporary Clinical Trials</i> , 2022, 117, 106767.	1.8	6
4	ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. <i>Current Atherosclerosis Reports</i> , 2022, 24, 585-597.	4.8	8
5	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f50-f60.	3.0	24
6	Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1562-1573.	3.4	12
7	Patterns of Recovery in Cardiovascular Care after the COVID-19 Pandemic Surge. <i>American Journal of the Medical Sciences</i> , 2021, , .	1.1	1
8	Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 774418.	2.4	23
9	Vitamin K2 Status and Arterial Stiffness Among Untreated Migraine Patients: A Case-Control Study. <i>Headache</i> , 2020, 60, 589-599.	3.9	10
10	Dual Antiplatelet Therapy Following PCI for NSTEMI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2447-2449.	2.8	1
11	The Impact of the COVID-19 Pandemic on Cardiovascular Fellows-in-Training. <i>Journal of the American College of Cardiology</i> , 2020, 76, 871-875.	2.8	24
12	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019, 03, e103-e108.	1.4	1
13	Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post-Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS-TIMI 46 and ATLAS ACS-TIMI 51. <i>Journal of the American Heart Association</i> , 2019, 8, .	3.7	10
14	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019, 139, 1234-1236.	1.6	7
15	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). <i>American Journal of Cardiology</i> , 2019, 123, 355-360.	1.6	6
16	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019, 208, 81-90.	2.7	25
17	Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 186-193.	1.0	12
18	Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment. <i>International Urology and Nephrology</i> , 2018, 50, 1075-1083.	1.4	30

#	ARTICLE	IF	CITATIONS
19	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018, 198, 84-90.	2.7	19
20	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 1-8.	2.1	14
21	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2046-2052.	3.4	48
22	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1896-1901.	1.6	17
23	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018, 02, e16-e24.	1.4	8
24	When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. <i>American Heart Journal</i> , 2017, 189, 1-8.	2.7	14
25	Collateral Circulation in Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 915-917.	2.9	2
26	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 237-245.	1.5	11
27	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 457-465.	2.7	48
28	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 457-465.	2.1	11
29	Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	40
30	Vitamin K2 supplementation and arterial stiffness among renal transplant recipients: a single-arm, single-center clinical trial. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 589-597.	2.3	49
31	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017, 01, e56-e65.	1.4	94
32	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017, 135, 323-333.	1.6	86
33	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. <i>Circulation</i> , 2017, 135, 648-655.	1.6	61
34	Etiology of End-Stage Renal Disease and Arterial Stiffness among Hemodialysis Patients. <i>BioMed Research International</i> , 2017, 2017, 1-6.	1.9	12
35	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. <i>Circulation</i> , 2016, 134, 1918-1930.	1.6	148
36	Medical education in a foreign language and history-taking in the native language in Lebanon: a nationwide survey. <i>BMC Medical Education</i> , 2016, 16, 298.	2.4	17

#	ARTICLE	IF	CITATIONS
37	Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003114.	3.9	14
38	Change in Pulse Wave Velocity and Short-Term Development of Cardiovascular Events in the Hemodialysis Population. <i>Journal of Clinical Hypertension</i> , 2016, 18, 857-863.	2.0	11
39	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. <i>American Heart Journal</i> , 2016, 180, 22-28.	2.7	25
40	Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). <i>American Journal of Cardiology</i> , 2016, 118, 625-631.	1.6	8
41	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , 2016, 375, 2423-2434.	27.0	1,265
42	EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2016, 37, 1296.1-1303.	2.2	112
43	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 227-232.	2.0	9
44	Pheochromocytoma Presenting as Partial HELLP Syndrome. <i>Case Reports in Obstetrics and Gynecology</i> , 2015, 2015, 1-3.	0.3	2
45	Renal Function Decline in Recipients and Donors of Kidney Grafts: Role of Aortic Stiffness. <i>American Journal of Nephrology</i> , 2015, 41, 57-65.	3.1	8
46	Dual Pathway Therapy for Secondary Prevention Following Acute Coronary Syndrome. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	2.0	0
47	d-Dimer elevation and adverse outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 55-59.	2.1	75
48	Organ procurement: should we teach undergraduate medical and nursing students?. <i>Experimental and Clinical Transplantation</i> , 2015, 13 Suppl 1, 55-8.	0.2	0
49	Outcome Of Bone Marrow Transplantation In Lebanese Children With β^2 -Thalassemia Major. <i>Blood</i> , 2013, 122, 5505-5505.	1.4	0